ArticleGut2021
Integrated genomic profiling and modelling for risk stratification in patients with advanced oesophagogastric adenocarcinoma.
Open access · greenAbstract read
In one paragraph
Article in Gut, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 20 papers.
0numbers the graph read from it
0cells of the map it votes in
20citing papers in PubMed
3.2field-weighted citation impact, top 6% of its field
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
20 citing papers in PubMed, 33 citations in OpenAlex.
- Exploring the origins of esophagogastric junction cancer through omics: A focus on the Siewert II subclassification.Surgery today · 2026Review
- The biology and therapeutic implications of heterogeneity in Barrett oesophagus and oesophageal adenocarcinoma.Nature reviews. Clinical oncology · 2026Review
- Multi-omics sequencing of gastroesophageal junction adenocarcinoma reveals prognosis-relevant key factors and a novel immunogenomic classification.Gastric cancer : official journal of the International Gastric Cancer Association and the Japanese Gastric Cancer Association · 2025Article
- Malignant epithelia cells-derived spermine induces APOE+ macrophages to suppress tumor immunity in adenocarcinoma of the esophagogastric junction.Frontiers in medicine · 2025Article
- New direction: identification of immunoinflammatory subtypes and potential therapeutic targets for cholangiocarcinoma.Discover oncology · 2024Article
- Article
- Development and validation of a nomogram to predict the survival and estimate surgical benefits for gastric cancer with liver metastasis receiving primary tumor resection.Frontiers in oncology · 2024Article
- Evolution of immune and stromal cell states and ecotypes during gastric adenocarcinoma progression.Cancer cell · 2023Article
- Model construction and risk analysis of the lncRNA genes associated with the prognosis of esophageal adenocarcinoma with immune infiltration.Journal of gastrointestinal oncology · 2023Article
- Integrative proteomic characterization of adenocarcinoma of esophagogastric junction.Nature communications · 2023Article
- Tumor-derived IL-8 facilitates lymph node metastasis of gastric cancer via PD-1 up-regulation in CD8Cancer immunology, immunotherapy : CII · 2022Article
- APOBEC3: Friend or Foe in Human Papillomavirus Infection and Oncogenesis?Annual review of virology · 2022Review
- Characterization of genomic alterations and neoantigens and analysis of immune infiltration identified therapeutic and prognostic biomarkers in adenocarcinoma at the gastroesophageal junction.Frontiers in oncology · 2022Article
- Integration of Tumor Heterogeneity for Recurrence Prediction in Patients with Esophageal Squamous Cell Cancer.Cancers · 2021Article
- Multi-omics consensus ensemble refines the classification of muscle-invasive bladder cancer with stratified prognosis, tumour microenvironment and distinct sensitivity to frontline therapies.Clinical and translational medicine · 2021Article
- Development of immune gene pair-based signature predictive of prognosis and immunotherapy in esophageal cancer.Annals of translational medicine · 2021Article
- Review
- Comprehensive Analysis of Alteration Landscape and Its Clinical Significance of Mitochondrial Energy Metabolism Pathway-Related Genes in Lung Cancers.Oxidative medicine and cellular longevity · 2021Article
- Identification of a Prognosis-Related Risk Signature for Bladder Cancer to Predict Survival and Immune Landscapes.Journal of immunology research · 2021Article
- Rapidly Evolving Treatment Landscape for Metastatic Esophagogastric Carcinoma: Review of Recent Data.OncoTargets and therapy · 2021Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
31 authors at 2 institutions in 2 countries.
Dapeng HaoDepartment of Genomic Medicine, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA.ORCID 0000-0002-9043-371X
Siyuan HeDepartment of Genetics, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA.
Kazuto HaradaGastroenterological Surgery, Kumamoto University, Kumamoto, Kumamoto, Japan.
Melissa Pool PizziDepartment of Gastrointestinal Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA.
Yang LuDepartment of Nuclear Medicine, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA.ORCID 0000-0001-9571-4679
Pujun GuanDepartment of Genomic Medicine, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA.ORCID 0000-0002-7288-9369
Lu ChenDepartment of Genomic Medicine, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA.
Ruiping WangDepartment of Genomic Medicine, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA.
Shaojun ZhangDepartment of Genomic Medicine, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA.ORCID 0000-0001-5760-5797
Matheus Sewastjanow-SilvaDepartment of Gastrointestinal Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA.ORCID 0000-0003-4804-1891
Ahmed AbdelhakeemDepartment of Gastrointestinal Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA.
Namita ShanbhagDepartment of Gastrointestinal Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA.
Manoop BhutaniGastroenterology Hepatology and Nutrition, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA.
Guangchun HanDepartment of Genomic Medicine, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA.
Jeffrey H LeeGastroenterology Hepatology and Nutrition, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA.
Shuangtao ZhaoDepartment of Genomic Medicine, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA.
Brian WestonGastroenterology Hepatology and Nutrition, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA.
Mariela Blum MurphyDepartment of Gastrointestinal Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA.
Rebecca WatersPathology, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA.
Jeannelyn Santiano EstrellaPathology, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA.
Sinchita Roy-ChowdhuriPathology, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA.
Qiong GanPathology, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA.
Ju-Seog LeeSystems Biology, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA.
Guang PengClinical Cancer Prevention, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA.
Samir M HanashTranslational Molecular Pathology, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA.
George Adrian CalinTranslational Molecular Pathology, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA.ORCID 0000-0002-7427-0578
Xingzhi SongComputational Genomics, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA.
Jianhua ZhangComputational Genomics, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA.
Shumei SongDepartment of Gastrointestinal Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA.ORCID 0000-0002-8128-6287
Linghua WangDepartment of Genomic Medicine, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA jajani@mdanderson.org LWang22@mdanderson.org.ORCID 0000-0001-9380-0266
Jaffer A AjaniDepartment of Gastrointestinal Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA jajani@mdanderson.org LWang22@mdanderson.org.ORCID 0000-0001-9946-0629
The University of Texas MD Anderson Cancer Center · USKumamoto University · JP
Funding
Tumor Evolution and Metastasis ProgramP30CA016672 · NCI · UNIVERSITY OF TX MD ANDERSON CAN CTR · PI Fabien Delerue · 1985 to 2026
$290.8MClonal Reconstruction and Targeting of the Correa SequenceR01CA241600 · NCI · UNIVERSITY OF HOUSTON · PI MCKEON, FRANK D. · 2019 to 2023
$2.3MThe Role of Telomere Shortening in MDS-AML Pathogenesis (resubmission)R01CA160433 · NCI · JOHNS HOPKINS UNIVERSITY · PI ARMANIOS, MARY Y · 2012 to 2016
$1.7MPrediction of Pathologic Complete Response by Gene Expression Profiling in EsophaR01CA138671 · NCI · UNIVERSITY OF TX MD ANDERSON CAN CTR · PI AJANI, JAFFER A. · 2010 to 2014
$1.5MInhibition of Hedgehog Signaling in Gli-1+Adeno CA of the Esoph or GE junctionR01CA172741 · NCI · UNIVERSITY OF TX MD ANDERSON CAN CTR · PI AJANI, JAFFER A. · 2013 to 2017
$1.4MMolecular Biomarkers as Classifiers to Individualize Therapy of Esophagus CancerR21CA129906 · NCI · UNIVERSITY OF TX MD ANDERSON CAN CTR · PI AJANI, JAFFER A. · 2009 to 2010
$367kMolecular Markers of Response to Chemoradiation in Localized Esophageal CancerR21CA127672 · NCI · UNIVERSITY OF TX MD ANDERSON CAN CTR · PI AJANI, JAFFER A. · 2008 to 2009
$312kNCI NIH HHS P30 CA016672NCI NIH HHS R01 CA138671NCI NIH HHS R01 CA160433NCI NIH HHS R01 CA172741NCI NIH HHS R01 CA241600NCI NIH HHS R21 CA127672NCI NIH HHS R21 CA129906
Abstract
objectivePrognosis of patients with advanced oesophagogastric adenocarcinoma (mEGAC) is poor and molecular determinants of shorter or longer overall survivors are lacking. Our objective was to identify molecular features and develop a prognostic model by profiling the genomic features of patients with mEGAC with widely varying outcomes.
designWe profiled 40 untreated mEGACs (20 shorter survivors <13 months and 20 longer survivors >36 months) with whole-exome sequencing (WES) and RNA sequencing and performed an integrated analysis of exome, transcriptome, immune profile and pathological phenotypes to identify the molecular determinants, developing an integrated model for prognosis and comparison with The Cancer Genome Atlas (TCGA) cohorts.
results
conclusionThis study discovered novel molecular features prognosticating overall survival in patients with mEGAC and identified potential novel targets in shorter survivors.
Indexed as
Genetic ProfileAdenocarcinomaDNA Copy Number VariationsEsophageal NeoplasmsExome SequencingFemaleHumansMalePrognosisRisk AssessmentSequence Analysis, RNAStomach Neoplasmsgastric adenocarcinomaoesophageal cancer
Identifiers
What OpenQuestion holds
Textmetadata
LicenceTDM
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.